The use of nanoparticles (NPs) in nanomedicine holds great promise for the treatment of
diseases for which conventional therapies present serious limitations. Additionally, NPs can …

Liposomes are well recognised as effective drug delivery systems, with a range of products
approved, including follow on generic products. Current manufacturing processes used to …

Control over vesicle size during nanoscale liposome synthesis is critical for defining the
pharmaceutical properties of liposomal nanomedicines. Microfluidic technologies capable of …

Lipid nanoparticles (LNP) are the leading systems for in vivo delivery of small interfering
RNA (siRNA) for therapeutic applications. Formulation of LNP siRNA systems requires rapid …

Antioxidants (AOs) play a crucial role in the protection and maintenance of health and are
also integral ingredients in beauty products. Unfortunately, most of them are sensitive due to …

The discovery of potent new materials for in vivo delivery of nucleic acids depends upon
successful formulation of the active molecules into a dosage form suitable for the …

Recent years have witnessed an increased interest in the development of nanoparticles
(NPs) owing to their potential use in a wide variety of biomedical applications, including drug …

In recent years, advancements in the fields of microfluidic and lab-on-a-chip technologies
have provided unique opportunities for the implementation of nanomaterial production …

Lipid nanoparticles (LNPs) containing short-interfering RNA (LNP-siRNA systems) are a
promising approach for silencing disease-causing genes in hepatocytes following …

Despite the substantial body of research investigating the use of liposomes, niosomes and
other bilayer vesicles for drug delivery, the translation of these systems into licensed …